Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Segeberg – page 90

1 607 clinical trials in Bad Segeberg, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Segeberg at a glance
1 607
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 607 trials in Bad Segeberg

Open in trial search

Study on Ustekinumab and Guselkumab for Children with Active Juvenile Psoriatic Arthritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Study on Palbociclib and Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib
  • Sponsor:ABCSG GmbH

Crohn's disease

Not recruiting

Study on BI 706321 and Ustekinumab for Patients with Moderate to Severe Crohn's Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 706321
  • Sponsor:Boehringer Ingelheim International GmbH

Study of Encorafenib, Cetuximab, and Pembrolizumab for Patients with Untreated BRAF V600E-Mutant Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Pfizer Inc.

Study on Fenebrutinib and Teriflunomide for Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Fenebrutinib
  • Sponsor:F. Hoffmann-La Roche AG

Breast cancer+1

Not recruiting

Study of Tucatinib and Ado-Trastuzumab Emtansine for Patients with Advanced HER2+ Breast Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tucatinib
  • Sponsor:Seagen Inc.

Study on the Safety and Effectiveness of TAK-755 (Apadamtase Alfa) for Patients with Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Apadamtase Alfa
  • Sponsor:Baxalta Innovations GmbH

Angelman's syndrome

Not recruiting

Study on the Long-Term Safety of GTX-102 for Patients with Angelman Syndrome

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Apazunersen
  • Sponsor:Ultragenyx Pharmaceutical Inc.

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Study on Venetoclax, Azacitidine, and Cusatuzumab for Newly Diagnosed Acute Myeloid Leukemia Patients Not Suitable for Intensive Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:OncoVerity Inc.

IgA nephropathy

Not recruiting

Study on the Effectiveness and Safety of Iptacopan for Patients with Primary IgA Nephropathy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Study on the Effectiveness and Safety of Reparixin for Adults with Acute Respiratory Distress Syndrome

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Reparixin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Segeberg

What the registry says about research in the country

01 Cardiac Care & Anticoagulation

Research focusing on post-catheter ablation patients with atrial fibrillation, evaluating long-term oral anticoagulation versus antiplatelet therapy for reducing cerebral embolic events.

  • Stroke Prevention
  • Atrial Fibrillation Management
  • Anticoagulation Strategies

These trials aim to enhance patient outcomes following cardiac procedures.

02 Interventional Cardiology

Investigation of novel treatment approaches for patients with atrial fibrillation who have undergone coronary stent placement, comparing different antithrombotic therapy regimens.

  • Stent Management
  • Bleeding Risk Assessment
  • Antithrombotic Therapy

Research focused on optimizing post-procedural medication strategies.

03 Acute Cardiac Care

Studies examining treatment strategies for ST-Elevated Myocardial Infarction, comparing different approaches to dual antiplatelet therapy and evaluating imaging-guided revascularization techniques.

  • Myocardial Infarction Treatment
  • Revascularization Techniques
  • Imaging Guidance

Advanced research into optimal treatment pathways for heart attack patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.